Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

A tablet tool may empower women to prevent HIV — trial puts it to the test

NCT ID NCT04621760

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests a tablet-based decision support tool designed to help women learn about their HIV risk and prevention options, including PrEP. Women aged 18-45 who are not living with HIV will be randomly assigned to use the tool before a clinic visit or to receive standard counseling. Researchers will survey participants about their knowledge, confidence, and satisfaction, and follow up after three months to see if they started an HIV prevention method. The goal is to see if the tool increases PrEP use and improves decision-making.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A tablet-based decision support tool that educates women about HIV prevention options, including PrEP.
What this could lead to
If effective, this tool could help more women at risk of HIV start using PrEP or other prevention methods, potentially reducing HIV rates among women of color.
What could go wrong
The trial is small and tests a behavioral tool, not a drug. Results may not apply broadly, and the tool's impact on actual HIV prevention is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

189 people

The number who actually took part.

Started

May 2021

Finished

Nov 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Self-identify as a woman (regardless of pregnancy status) * Age 18 - 45 years * Not known to be living with HIV (based on self-report) * English-speaking * Interested in participating Exclusion Criteria: * Unable to consent * Currently using PrEP * Those who were assigned male at birth and self-identify as a man * Unwilling to be contacted in 3 months * Already participated in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human immunodeficiency virus transmission are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Florida Department of Health in Duval County

    Jacksonville, Florida, 32211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.